Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 3/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686670 | 1.00 | PIK3CA (0.44) | PIK3CAMTORHDAC1HDAC2RORC | |
| SCHEMBL18201812 | 0.93 | CYP3A4 (0.48) | PIK3CAMTORCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20528288 | 0.92 | CYP1A2 (0.47) | PIK3CAMTORHDAC1HDAC2RORC | |
| SCHEMBL18201811 | 0.90 | RORC (0.49) | PIK3CAMTORRORCCYP11B2OPRD1 | |
| SCHEMBL1997213 | 0.87 | MEN1 (0.49) | TBK1 | |
| SCHEMBL30584532 | 0.87 | MEN1 (0.49) | TBK1 | |
| SCHEMBL25291826 | 0.85 | PPARD (0.51) | RORCCYP11B2ACACBCYP3A4CYP2D6 | |
| SCHEMBL29687028 | 0.85 | RORC (0.42) | PIK3CAMTORRORCOPRD1OPRK1 | |
| SCHEMBL18201923 | 0.85 | RORC (0.42) | PIK3CAMTORRORCOPRD1OPRK1 | |
| SCHEMBL16892030 | 0.84 | ACACB (0.44) | RORCCYP11B2ACACBSCD5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | FOCHON BIOSCIENCES, LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
| WO-2016173505-A1 | CERTAIN PROTEIN KINASE INHIBITOR | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450316-B2 | Certain protein kinase inhibitor | CDK4, CDK6, CDK2 | PIK3CA 79/4885MTOR 100/4885HDAC1 983/4885 |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | CDK4, CDK6, CDK2 | PIK3CA 49/4885MTOR 80/4885HDAC1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.